Midazolam Pediatric Dose — Status Epilepticus
Midazolam is a short-acting benzodiazepine that potentiates GABA-mediated inhibitory neurotransmission to terminate seizure activity. It is a first-line agent for the acute management of status epilepticus in pediatric patients, particularly when intravenous access cannot be rapidly established. Its rapid intramuscular absorption makes it a practical and effective option in both prehospital and emergency department settings.
Pediatric Dosing
For status epilepticus when no IV access is available, administer midazolam 0.1–0.3 mg/kg IM. The maximum single dose is 10 mg.
- Route: Intramuscular (IM)
- Dose range: 0.1–0.3 mg/kg per dose
- Maximum single dose: 10 mg
Worked example: For a 20 kg child: 20 × 0.1 mg/kg = 2 mg (low end) to 20 × 0.3 mg/kg = 6 mg (high end). For a 40 kg child, the upper-end calculation of 12 mg would be capped at the maximum of 10 mg. Consult institutional protocol for repeat dosing intervals.
Indications and Clinical Context
Midazolam IM is indicated for the termination of active seizures or status epilepticus in pediatric patients when intravenous or intraosseous access is not immediately available. Benzodiazepines remain the cornerstone of first-line therapy for status epilepticus per PALS and established emergency neurology guidelines, with the goal of achieving seizure cessation within the first 5–10 minutes of a generalized convulsive episode.
The intramuscular route is particularly valuable in the prehospital environment, in young children with difficult venous access, or in any clinical scenario where delays in IV placement would otherwise defer treatment. Midazolam IM has demonstrated non-inferior or superior efficacy compared to IV lorazepam in several pediatric trials, supporting its role as a reliable alternative when parenteral access is unavailable.
Administration and Monitoring
Administer as a single IM injection into the anterolateral thigh or deltoid, using an appropriately sized needle for the patient’s muscle mass. Onset of action via the IM route is generally within 5–10 minutes. The maximum single dose is 10 mg regardless of weight. Monitor continuously for respiratory depression, oxygen desaturation, and hypotension following administration; have resuscitative equipment and personnel immediately available.
- Route: IM only per this dosing description; IV/IO routes are preferred once access is established
- Key adverse effects: Respiratory depression, apnea, hypotension, excessive sedation
- Contraindications: Known hypersensitivity to midazolam or benzodiazepines
- Monitoring: Continuous pulse oximetry, respiratory rate, blood pressure, and level of consciousness
- Consult institutional protocol for maximum cumulative dose and redosing intervals
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.